BioLizard, a leading bioinformatics, data analytics and data engineering consulting company driving digital transformation in the life sciences industry, has been awarded a grant from Flanders Innovation & Entrepreneurship (VLAIO) to develop an AI-powered biomedical knowledge discovery software solution that will be part of BioLizard’s Bio|Verse suite. This innovative application will be designed to automate and streamline literature analysis, enabling biotech and pharmaceutical companies to extract critical insights from vast amounts of (un)structured data with unprecedented speed and accuracy.
With over one million biomedical research articles published annually on PubMed alone, reviewing literature is an overwhelming but imperative part of drug development and scientific advancements. It is estimated that research scientists spend about 60% of their time selecting, organizing and cleaning data. Thus, there is a critical need for a solution that can automate and streamline this process, ensuring faster, more reliable and more comprehensive biomedical information extraction. The novel solution developed in the Bio|Verse framework will leverage LLMs to automatically search, extract, and structure information, transforming unstructured text into actionable insights for target identification, drug discovery, and other life sciences applications. The knowledge output gained from structured and unstructured data searches is presented in visual and interactive dashboards allowing visual analytics and biological interpretation.
“We are grateful to VLAIO for awarding us this important grant to provide researchers a critical new application which will assist them in making discoveries that may one day improve and even save lives,” said Liesbeth Ceelen, CEO of BioLizard. “Leveraging our extensive expertise in biotechnology and AI-based software solutions, our next step in the Bio|Verse suite of applications will take literature and data review to a new level. This AI-driven tool will significantly reduce the time researchers spend on data gathering, allowing them to focus on what they do best – analyzing and interpreting the data.” She added: “By integrating this tool into Bio|Verse, we will enable our biotech and pharmaceutical clients to improve target identification, accelerate drug discovery, and gain actionable insights faster and more reliably than ever before.”
The grant will accelerate the development of this novel application. This new step in our AI capabilities will enable the integration of public and non-public resources for knowledge extraction. The application will be a value add in the services provided by BioLizard.